Pathology of high dose intermittent cyclophosphamide therapy.

Human Pathology
R E SlavinG M Mullins

Abstract

Pathologic changes induced by high dose intermittent cyclophosphamide therapy are described in 39 patients with solid tumors, lymphohematopoietic malignant disease, and bone marrow transplants. Patients receiving 50 to 120 mg. per kg. daily for one to four days showed transmural bladder injury affecting all component tissue; toxic vasculitis involving small arteries, capillaries, and venules; and interstitial, myocardial, and vascular changes in the heart. Myocardial necrosis with heart failure was the dose limiting factor of very high dose therapy. Patients receiving 15 to 30 mg. per kg. for four days showed variable degrees of bladder injury limited to the mucosa and lamina propria and vascular changes consisting only of telangiectasia. Both groups showed atypia of transitional urinary and esophageal epithelia as well as of mesenchymal cells in the lamina propria of the bladder, persistent and total ablation of spermatogenesis, and long lasting absence of ovarian follicular maturation. Bone marrow hypoplasia and lymphoid depletion developing after cyclophosphamide therapy completely disappeared an average of 3.5 weeks after the last dose.

References

Feb 11, 1971·The New England Journal of Medicine·W W Johnson, D C Meadows
May 1, 1972·The Journal of Pediatrics·R E CookeJ P Dorst
Nov 29, 1973·The New England Journal of Medicine·G L WarneF I Martin
Apr 1, 1971·The American Journal of Medicine·J J MillerJ C Leissring
Sep 1, 1966·The Journal of Urology·J S Rubin, R T Rubin
Apr 15, 1966·Klinische Wochenschrift·I Oppers, H Gerhartz
May 1, 1967·Cancer·N Brock, H J Hohorst
May 1, 1967·The Journal of Urology·E E AndersonJ F Glenn

❮ Previous
Next ❯

Citations

Feb 1, 1979·Arthritis and Rheumatism·M J Wilkenfeld, A J Sliwinski
May 15, 1990·Cancer·W J BakerR B Weiss
Aug 1, 1983·The Journal of Urology·R G Rowland, J N Eble
Jan 1, 1981·Medical and Pediatric Oncology·L J SteinherzD R Miller
Feb 25, 1982·The New England Journal of Medicine·UNKNOWN Arbeitsgemeinschaft für Pädiatrische Nephrologie
Oct 28, 2014·International Journal of Molecular Sciences·Sun-A ImChong-Kil Lee
Feb 13, 2002·Bone Marrow Transplantation·J T Beranek
Jun 28, 2005·Paediatric Drugs·Valeriano C SimbreSteven E Lipshultz
Jan 1, 1991·Cancer Chemotherapy and Pharmacology·J P EderK H Antman
Apr 1, 1977·Cancer·J C Gonzales-VitaleS S Sternberg
Jul 1, 1982·Canadian Anaesthetists' Society Journal·F Chung
May 9, 2001·The American Journal of Surgical Pathology·W H WestraD W Eisele
Oct 23, 2013·Pediatric and Developmental Pathology : the Official Journal of the Society for Pediatric Pathology and the Paediatric Pathology Society·Emily E MeserveJames L Labelle
Mar 4, 2019·Current Oncology Reports·Mirela TuzovicEric H Yang
Oct 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Justin D FloydMichael C Perry
Mar 23, 2011·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Tom McCullochAlan R Watson
Aug 1, 1981·The Journal of Urology·J V ThachilW D Rider
Jan 1, 1990·Pharmacology & Therapeutics·J M Patel
Apr 1, 1988·Baillière's Clinical Gastroenterology·K Ewe
Jul 13, 2005·Phytomedicine : International Journal of Phytotherapy and Phytopharmacology·K B H Kumar, R Kuttan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.